$4.70
-0.42%Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
KLRS • NASDAQ
| Kalaris Therapeutics Inc Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||
-43.4M | -58.8M | -14.7M | -15.5M | -172M | -69.8M | |
13K | 0.0 | 0.0 | 0.0 | 1.1M | 73K | |
0.0 | 0.0 | 148K | 271K | 0.0 | 0.0 | |
-3M | 16.4M | 1.5M | 2M | 45.2M | 9.9M | |
3.4M | -25.3M | -1.1M | 3.4M | 19.4M | -1M | |
-43M | -67.7M | -14.1M | -9.8M | -106.3M | -60.8M | |
INVESTING ACTIVITIES | ||||||
-200K | (0.0) | (0.0) | (0.0) | -26K | -235K | |
-34.5M | (0.0) | (0.0) | (0.0) | -76.6M | -300.3M | |
15M | 95M | 0.0 | 0.0 | 262.6M | 131M | |
-19.7M | (95M) | (0.0) | (0.0) | (186M) | -169.5M | |
FINANCING ACTIVITIES | ||||||
50M | 21K | 0.0 | 0.0 | 232K | 292M | |
7.5M | 0.0 | 6M | 4.3M | 0.0 | 0.0 | |
102.1M | 0.0 | 1.5M | 5K | 0.0 | 0.0 | |
159.6M | 21K | 14.2M | 12.8M | 232K | 292M | |
CASH FLOW SUMMARY | ||||||
-117.1M | 852K | 0.0 | 0.0 | -896K | -90K | |
-20.2M | 28.2M | 110K | 3M | 79M | 61.6M | |
118.3M | 90.1M | 3.1M | 58K | 122.7M | 61.1M | |
98.1M | 118.3M | 3.2M | 3.1M | 201.7M | 122.7M | |
-43.2M | -67.7M | -14.1M | -9.8M | -106.3M | -61M |
KLRS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 03, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 10, 2026 | April 08, 2026 | 2026 | |
S-3 S-3 N/A | April 03, 2026 | April 03, 2026 | ||
S-3 S-3 N/A | April 03, 2026 | April 03, 2026 | ||
10-K 10-K 2025 FY FY | March 17, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 17, 2026 | March 17, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 09, 2026 | March 09, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 18, 2025 | December 17, 2025 | 2025 |
Continue your KLRS research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.